血清Claudin-5水平有助于重症急性胰腺炎的早期预测:一项前瞻性观察性研究
该前瞻性观察性研究纳入2021年12月1日至2022年11月30日苏北人民医院收治的109例急性胰腺炎患者(轻症66例、中重症15例、重症28例)及27例健康志愿者。采用酶联免疫吸附试验检测血清Claudin-5水平,并按2012年亚特兰大分类标准分组。结果发现,随着病情加重,血清Claudin-5水平显著升高且均高于健康对照组,与CRP、PCT、HCT及mMarshall、mCTSI、BISAP评分呈正相关,与Alb呈负相关。ROC曲线分析显示,血清Claudin-5早期预测重症急性胰腺炎的AUC为0.948,以2997 ng/L为界值时敏感性100%、特异性88.89%。多因素岭回归分析显示,血清Claudin-5水平、PCT和APACHE II评分可作为早期预测重症急性胰腺炎的独立危险因素。
要点
- 急性胰腺炎患者血清Claudin-5水平随病情加重而升高,轻症、中重症、重症组均显著高于健康对照组(均P<0.05)。
- 重症急性胰腺炎患者入院3天时血清Claudin-5水平较入院1天时显著下降[ng/L:2052.59(1089.43,4006.47)比4667.81(3935.21,7315.66),P<0.05]。
- 血清Claudin-5早期预测重症急性胰腺炎的AUC为0.948,以≥2997 ng/L为界值时敏感性100%、特异性88.89%。
- 血清Claudin-5水平、PCT和APACHE II评分可作为早期预测重症急性胰腺炎的独立危险因素(均P<0.05)。
- 血清Claudin-5与CRP、PCT、HCT及mMarshall、mCTSI、BISAP评分呈显著正相关(r值分别为0.570、0.525、0.323、0.774、0.670、0.652,均P<0.001),与Alb呈显著负相关(r=-0.394,P<0.001)。
适用人群与场景
- 2021年12月1日至2022年11月30日苏北人民医院收治的、依据2012年亚特兰大分类标准诊断为急性胰腺炎的患者。
- 同期随机选取的合格健康志愿者作为健康对照组。
诊断标准与关键阈值
- 采用2012年亚特兰大分类标准将急性胰腺炎患者分为轻症急性胰腺炎组、中重症急性胰腺炎组和重症急性胰腺炎组。
- 血清Claudin-5水平≥2997 ng/L时,早期筛查重症急性胰腺炎的敏感性为100%、特异性为88.89%。
研究设计与关键结果
- 研究类型为前瞻性观察性研究,共纳入109例急性胰腺炎患者(轻症组66例、中重症组15例、重症组28例)和27例健康志愿者。
- 入组各组间性别和年龄差异无统计学意义,三组急性胰腺炎患者间基础疾病和病因构成差异无统计学意义。
- 随着疾病进展,各组急性胰腺炎患者血清Claudin-5水平均显著高于健康对照组[ng/L:轻症组888.58(574.52,1141.59)、中重症组3749.02(2784.93,5789.92)、重症组4667.81(3935.21,7315.66)比健康对照组291.13(250.19,314.75),均P<0.05]。
- 亚组分析显示,重症急性胰腺炎患者入院3天时血清Claudin-5水平较入院1天时显著下降[ng/L:2052.59(1089.43,4006.47)比4667.81(3935.21,7315.66),P<0.05]。
- Spearman相关分析显示,急性胰腺炎患者血清Claudin-5水平与CRP、PCT、HCT及mMarshall、mCTSI、BISAP评分呈显著正相关(r值分别为0.570、0.525、0.323、0.774、0.670、0.652,均P<0.001),与Alb呈显著负相关(r=-0.394,P<0.001)。
- 急性胰腺炎患者随着疾病进展,HCT水平升高、Alb水平降低,趋势显著(均P<0.05)。
- 重症急性胰腺炎患者治疗后上述现象改善,间接提示血清Claudin-5水平是血管渗漏的正向指标。
- ROC曲线分析显示,血清Claudin-5水平对急性胰腺炎患者早期预测重症急性胰腺炎的准确性最高,AUC为0.948;以≥2997 ng/L为界值时敏感性100%、特异性88.89%。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对急性胰腺炎患者,入院早期检测血清Claudin-5水平可能有助于早期识别重症急性胰腺炎高危患者(作者结论:血清Claudin-5水平有助于重症急性胰腺炎的早期预测,并与炎症反应和血管渗漏密切相关)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the value of early tight junction protein Claudin-5 levels in predicting the severity of acute pancreatitis (AP).
METHODS: A prospective observational study was conducted, including patients diagnosed with AP and admitted to the Northern Jiangsu People's Hospital from December 1, 2021 to November 30, 2022. Eligible healthy volunteers were randomly selected to serve as healthy controls during the same period. Patients were classified into mild acute pancreatitis (MAP) group, moderate-severe acute pancreatitis (MSAP) group, and severe acute pancreatitis (SAP) group based on the 2012 Atlanta classification criteria. Patients with SAP were then divided into three subgroups of 1, 3, and 7 days based on the duration of hospitalization. Baseline data, such as gender, age, underlying disease, and probable etiology, was collected from all enrolled individuals. The enzyme-linked immunosorbent assay (ELISA) was employed to detect serum Claudin-5 levels in each cohort of enrollees. Data on additional serologic indicators, including hematocrit (HCT), albumin (Alb), serum Ca2+, C-reactive protein (CRP), and procalcitonin (PCT) levels, were obtained via the in-hospital test query system in each group of patients with AP. The modified Marshall score (mMarshall), modified CT severity index (mCTSI) score, bedside severity index of severity in acute pancreatitis (BISAP) score, and acute physiology and chronic health evaluation II (APACHE II) were recorded for each group of patients with AP. Differences in the above indicators between groups were analyzed and compared. Spearman's correlation method was employed to examine the relationship between Claudin-5 levels and each influential factor. The receiver operator characteristic curve (ROC curve) was plotted to analyze the predictive value of each influencing factor on SAP. Ridge regression was used to screen for independent risk factors for SAP.
RESULTS: A total of 109 patients with AP were enrolled, comprising 66 in the MAP group, 15 in the MSAP group, and 28 in the SAP group. Additionally, 27 healthy volunteers were enrolled as the healthy control group. No statistically significant differences were observed in gender and age among the enrolled groups, and no statistically significant differences were identified among the three groups of patients with AP in terms of underlying disease and etiologic composition. As the disease progressed, serum Claudin-5 levels exhibited a notable increase across all AP patient groups, and they were all significantly higher than those in the healthy control group [ng/L: 888.58 (574.52, 1 141.59), 3 749.02 (2 784.93, 5 789.92), 4 667.81 (3 935.21, 7 315.66) vs. 291.13 (250.19, 314.75), all P < 0.05]. Subgroup analyses showed that as the disease duration prolonged, patients in the SAP group exhibited a notable decline in Claudin-5 levels at 3 days post-admission, compared with those at 1 day post-admission [ng/L: 2 052.59 (1 089.43, 4 006.47) vs. 4 667.81 (3 935.21, 7 315.66), P < 0.05]. Spearman correlation analysis showed that serum Claudin-5 levels in patients with AP were significantly positively correlated with CRP, PCT, HCT, and mMarshall, mCTSI, and BISAP scores (r values were 0.570, 0.525, 0.323, 0.774, 0.670, 0.652, all P < 0.001), and significantly negatively correlated with Alb (r = -0.394, P < 0.001). A significant trend was observed in patients with AP, with an increase of HCT levels and a decrease of Alb levels as the disease progressed (both P < 0.05). An improvement of aforementioned phenomena was observed in patients with SAP following treatment, indirectly indicating that serum Claudin-5 level was a positive indicator of vascular leakage. ROC curve analysis showed that serum Claudin-5 levels in patients with AP exhibited the highest accuracy for early prediction of SAP, with the area under the ROC curve (AUC) of 0.948. When serum Claudin-5 levels ≥2 997 ng/L, the sensitivity for early screening for SAP was 100% and the specificity was 88.89%. Multifactorial ridge regression analysis showed that serum Claudin-5 level, PCT and APACHE II score could be used as independent risk factors for early prediction of SAP (all P < 0.05).
CONCLUSIONS: Serum Claudin-5 levels facilitate early prediction of SAP and are strongly associated with inflammatory response and vascular leakage.
参考来源
- Chen X, Wang H, Geng P, et al. [Serum Claudin-5 levels facilitate the early prediction of severe acute pancreatitis: a prospective observational study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39380513. doi:10.3760/cma.j.cn121430-20240318-00247
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。